Placebo-Controlled, Double-Blind, Parallel Group, Fixed Dose Study of KW-6002 (Istradefylline) in the Treatment of Parkinson's Disease (Phase 3).

Trial Profile

Placebo-Controlled, Double-Blind, Parallel Group, Fixed Dose Study of KW-6002 (Istradefylline) in the Treatment of Parkinson's Disease (Phase 3).

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Feb 2017

At a glance

  • Drugs Istradefylline (Primary)
  • Indications Parkinson's disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Kyowa Hakko Kirin
  • Most Recent Events

    • 25 Mar 2013 Istradefylline has been approved in Japan according to a media release from Kyowa Hakko Kirin.
    • 24 May 2012 Actual end date (February 2011) added as reported by ClinicalTrials.gov.
    • 22 May 2012 Actual initiation date changed from 1 Jun 2009 to 1 Jul 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top